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ABSTRACT 
 
 
Aims: To identify the most commonly reported HIV indicator conditions (HIV ICs) found in or 
associated with HIV infection and to review interventions incorporating HIV ICs to aid or guide 
offering of an HIV test and discuss their effectiveness in increasing HIV testing rates and 
diagnosing new cases of HIV-infection. 
Methodology: The following electronic databases were searched; OVID Medline, Google, Web of 
Science and PubMed. We included studies conducted in high income countries within the adult 
population (>18yrs of age) that were published in the era of combination antiretroviral therapy 
between 1996 and 2016. We excluded studies relating to HIV testing or screening of pregnant 
women. 
Results: We identified 42 studies investigating ICs associated with HIV infection either prior to or 
after diagnosis within primary, secondary and tertiary care settings. The most common ICs and 
symptoms associated with HIV infection were; sexually transmitted infections (syphilis, chlamydia, 
gonorrhoea and condyloma acuminata) and blood borne viruses (Hepatitis C and Hepatitis B), 
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pneumonia, tuberculosis, blood dyscrasia, thrombocytopenia, oral and oesophageal candidiasis, 
seborrhoeic dermatitis, herpes zoster, Kaposi sarcoma, fever, weight loss, diarrhoea and 
lymphadenopathy. Twelve intervention studies that used HIV prediction tools and computer 
prompts based on HIV ICs demonstrated that these are effective in helping healthcare 
professionals to offer more targeted approaches to HIV testing.  
Conclusion: Our review may aid policy makers and healthcare professionals in developing 
strategies to improve and increase HIV testing in individuals that present with defined HIV ICs. ICs 
have the potential to be used more effectively as triggers for earlier HIV testing and importantly for 
patients to receive a more timely diagnosis.  
 
 
Keywords: HIV; indicator conditions; diagnosis; testing; screening; early detection; prompted; 
algorithm; HIV testing reminders. 
 
1. INTRODUCTION  
 
There are an estimated 101,200 people living 
with HIV in the UK of whom 13% have not yet 
been diagnosed and are unaware of their 
infection [1]. A similar percentage are found in 
other, socioeconomic equivalent countries [2,3]. 
Two thirds of new infections are likely to be 
transmitted from those unaware of their HIV 
status [4]. Treatment for HIV infection using anti-
retroviral treatment (ART) is highly effective but 
early and prompt diagnosis of infection are 
paramount for greatest benefit of treatment. 
Recent international recommendations now state 
that ART should be initiated in all individuals with 
HIV infection irrespective of CD4 cell count [5,6]. 
Late diagnosis of HIV is common in Europe with 
48% of HIV infected persons presenting with a 
CD4 cell count <350 cells/mm3 and 28% with 
CD4 count < 200 cells/mm
3 
in 2015 [7]. Late 
diagnosis is also a problem globally [8]. In 
England during 2015, 39% of adults newly 
diagnosed with HIV were diagnosed late (CD4 
count < 350 mm3) [9]. In areas of high 
prevalence (>2 per 1000 among 15-59-year 
old’s), the British HIV Association (BHIVA) 
national guidelines recommend that all new 
general practice registrants and all new hospital 
admissions should be tested for HIV [10]. In the 
USA, current guidance is for routine testing 
among all adults that come into contact with the 
healthcare system [11]. Patients often present to 
healthcare professionals (HCPs) with symptoms 
or conditions that are associated with HIV called 
HIV indicator conditions (HIV ICs). HIV ICs are 
diseases and symptoms that have been 
associated with underlying HIV infection of which 
37 HIV ICs have been documented [10]. In the 
primary care setting general practitioners (GP) 
are recommended to follow an indicator 
condition- guided testing approach [10,12]. All 
patients presenting with any HIV IC in primary 
care should be offered an HIV test. Research 
shows that often the GP or HCP are unfamiliar 
with HIV ICs and do not associate these 
conditions with HIV infection resulting in potential 
HIV diagnoses being missed [13,14]. There is the 
added complication that a high proportion of 
these conditions are nonspecific in nature and 
some symptoms resemble more mundane 
infections for which patients may often not seek 
medical advice. During the early stages of 
primary HIV infection (PHI) or acute retroviral 
syndrome (ARS) symptoms usually develop 
within 2 to 4 weeks after infection. Symptoms or 
seroconversion illness may be present in 23% to 
92% of infected cases [15]. Typical symptoms 
include fever, fatigue, rash, nausea and 
headache that usually last 2 to 3 weeks and 
often represent the only clinical signs of HIV 
infection until many years later when more 
advanced immunosuppression may occur. Many 
other diverse clinical conditions may also present 
with these symptoms [16]. Earlier diagnosis of 
HIV therefore requires innovative strategies to 
target testing towards individuals most likely to 
be infected. 
 
IC guided testing provides a valuable opportunity 
to identify individuals with undiagnosed HIV 
infection. A recent study showed that 27% of 
patients had presented for care at least once with 
HIV and/or AIDS associated conditions 3 years 
prior to receiving their diagnosis [17]. Because 
HCPs decide whether a test offer is appropriate 
based on the patient’s symptoms and not on 
race, ethnicity or sexuality, IC guided testing is 
less stigmatising. IC guided testing also removes 
the need for individual risk assessment and helps 
to normalise testing [18].  However, there is still a 
compelling need to educate clinicians and GPs 
about HIV and incorporating IC guided testing 
[19] in order to decrease rates of late diagnosis. 
A recent review of newly infected HIV patients in 
Germany found that ICs were present in one fifth 
of late presenters [20]. Scognamiglio et al. found 
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that approximately 30% of newly diagnosed 
adults with HIV infection had reported at least 
one IC before HIV diagnosis and that having an 
HIV test within 6 months of being diagnosed with 
an indicator disease reduced the risk of late 
presentation by 50%. The HIV Indicator Diseases 
Across Europe Study (HIDES) [21] has raised 
awareness of IC based testing and developed an 
indicator disease testing strategy in which 
patients were tested routinely for HIV if 
presenting with preselected ICs (HIDES I & II 
studies) [22,23]. Data from the HIDES II audit in 
patients accessing care for a number of HIV ICs 
highlighted that testing rates in those with ICs 
remained low across Europe [23]  with poor 
adherence to European guidelines 
recommending routine testing [21]. High HIV 
positivity rates were observed in individuals with 
AIDS defining and non-AIDS defining ICs within 
the HIDES study [23] and have also been 
reported in other studies [24]. Therefore, 
interventions are needed that prompt HCPs to 
offer a test when patients present with HIV ICs.  
 
We review data on the most commonly reported 
HIV ICs found in or associated with either acute 
or chronic HIV infection in individuals prior to or 
at HIV diagnosis. In addition, we review research 
studies of interventions that have used HIV ICs 
to guide/ increase HIV testing and explore which 
of these interventions have been most effective 
in increasing HIV testing rates and case finding. 
Our review may aid policy makers and HCPs in 
developing strategies to improve and increase 
HIV testing in individuals that present with 
defined HIV ICs, and show the potential of ICs as 
effective triggers for HIV testing that should 
decrease late diagnosis. 
  
2. MATERIALS AND METHODS  
 
2.1 Search Strategy 
 
We carried out a broad literature search of 
published documents that included peer 
reviewed articles in journals, reports and British 
HIV Association (BHIVA) conference 
proceedings. The following electronic databases 
were searched; OVID Medline, Google, Web of 
Science and PubMed. The search was last 
performed on 15
th
 November 2016. We used a 
combination of focused computerised retrieval 
and hand searching. Hand searching involved 
manual page by page examination of recent 
BHIVA conference proceedings to identify 
eligible studies (abstracts from 2010 to 2017). 
We also manually searched reference lists of 
relevant articles for additional publications.  
 
Basic searches were performed using a 
combination of the following keywords for ICs 
associated with HIV infection and interventions 
that had used HIV ICs  to guide testing; HIV 
clinical indicator conditions, HIV indicator 
diseases, HIV symptoms, HIV test*, screen* 
diagnos*, HIV testing guidelines, BHIVA 
guidelines, HIV testing in primary care, 
secondary care, HIV indicator conditions and 
interventions, HIV testing algorithms, clinical 
decision support tool and HIV testing, clinical 
prediction tool and HIV testing, electronic 
reminders and HIV testing, HIV testing and 
electronic systems, computer system data and 
HIV testing, general practice data and HIV 
testing.  
 
2.2 Selected Studies 
 
Papers included in the review had to meet the 
following inclusion criteria: studies conducted in 
high income countries that had investigated 
associations of ICs with HIV infection among 
adult populations (>18 years of age) and 
interventions that had used ICs to guide HIV 
testing published in the combination ART era 
(1996-2016). Documents had to be accessible 
through the University of Bristol institutional 
library service. We excluded studies relating to 
HIV testing or screening of pregnant women and 
HIV infection in children.    
  
3. RESULTS 
 
3.1 Associations of HIV Indicator 
Conditions (HIV ICs) with HIV 
Infection 
 
3.1.1 Characteristics of studies 
 
The review found 42 studies which investigated 
associations of ICs with testing positive for HIV 
infection (Table 1). Of these, 37 studied 
individuals prior to or after diagnosis, and 5 only 
studied signs and symptoms in individuals 
specifically diagnosed with acute HIV infection 
(AHI)/primary HIV infection (PHI).  
 
Studies included in this analysis were: peer 
reviewed papers (n= 35) abstracts from BHIVA 
conference proceedings (n= 7). Locations of 
included studies were: UK and Northern Ireland 
(n=14), France (n= 1), Italy (n= 1), Germany (n= 
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1), Spain (n=4), Sweden (n=1), Switzerland 
(n=1), Amsterdam (n=1), Denmark (n=2), Europe 
wide (n=4), Japan (n=1), Canada (n=1), USA (n= 
7), Brazil (n=1), Worldwide (n = 2).  Studies used 
a variety of different data collection methods 
including: cross sectional analysis (n= 4), 
prospective analysis (n= 6), retrospective 
analysis (n=19), retrospective/audit (n = 4), case 
note review (n=2), case/control studies (n=3), 
service evaluation (n=1), observational study 
(n=1) and information gathered from review 
articles (n= 2). Studies were carried out in the 
following settings: primary care (n= 8), secondary 
care (n= 17), both primary and secondary care 
settings (n=1), sexual health clinic & secondary 
care (n= 2), sexual health clinics (n=5), HIV and 
medical centres (n= 6), public health surveillance 
database (n= 1), collection of different settings 
(e.g reviews) (n= 2).  
 
3.1.2 Most commonly reported HIV indicator 
conditions (HIV ICs) and strongest 
associations of ICs with HIV infection 
 
A list was compiled of over 110 HIV ICs and 
symptoms reported across 42 studies which 
included approximately 105,500 HIV positive 
patients either prior to or after receiving a 
diagnosis of HIV. These studies were carried out 
across different healthcare settings (Table 1).  
The most commonly reported HIV-related 
conditions were; pneumonia and bacterial 
pneumonia (24 studies), herpes zoster (17 
studies), oral candidiasis and oesophageal 
candidiasis (14 studies), STIs (in general) (14 
studies), seborrhoeic dermatitis (12 studies), 
tuberculosis and pulmonary tuberculosis (8 
studies), Kaposi sarcoma (8 studies), blood 
dyscrasia (7 studies) and thrombocytopenia (7 
studies). The most common symptoms were 
diarrhoea (11 studies), fever/pyrexia (14 studies), 
weight loss (14 studies), and lymphadenopathy 
(17 studies).  
 
The healthcare setting in which the HIV ICs were 
identified is an important factor when considering 
the prevalence of each condition/disease. Some 
diseases are more likely to be diagnosed and 
treated in the primary care setting e.g. herpes 
zoster. However, compared to patients seen in 
general practice, those who need to be 
hospitalised are likely to present with more 
complex conditions associated with 
immunosuppression. Figs. 1 to 7 show some of 
the most commonly reported HIV ICs and the 
prevalence estimates reported for each IC by 
healthcare setting (primary, secondary or tertiary 
care), using studies with available data. 
 
To present results of our review of the most 
common reported HIV ICs we have grouped 
diseases into symptoms seen in PHI/AHI, STIs 
and blood borne viruses (BBVs), conditions 
associated with immunosuppression and cancers 
and finally other common conditions and 
symptoms. 
 
3.1.2.1 Primary HIV infection 
 
In the studies that analysed patients with PHI or 
AHI, the most commonly reported 
conditions/symptoms were fever/pyrexia of 
unknown origin, lymphadenopathy, rash, 
headache, weight loss and gastrointestinal 
symptoms (nausea, vomiting, diarrhoea). 
Lymphadenopathy was a condition commonly 
found in individuals reported as having PHI or 
AHI [25-28]. Strong associations of the presence 
of lymphadenopathy with PHI/AHI were reported 
in the following review articles; lymphadenopathy 
was present in 7-75% of patients with AHI [27], 
odds ratio of early HIV infection (versus 
uninfected)  in those reporting lymphadenopathy 
was 4.6 (95% CI 1.3-8) and the presence of 
lymphadenopathy was the most useful sign to 
indicate an individual with early HIV infection 
[28]. Other studies also showed that 
lymphadenopathy or swollen glands were 
common symptoms in individuals with PHI: 45% 
[25] and 21% [26]. 
 
Fever/pyrexia was also a commonly reported 
symptom in PHI or AHI; in individuals infected 
with HIV (91% were MSM) 55% had reported 
symptoms of fever [26] and among patients with 
AHI it was 77% [29].  In a review article by 
Richey & Halperin (2013), between 53-90% of 
patients presented with fever and in a 
multivariable analysis of individuals with PHI, 
fever (OR 5.2, 95% CI 2.3-11.7) and rash (OR 
4.8, 95% CI 2.4-9.8) were the symptoms most 
strongly associated with PHI and indicated the 
highest risk of HIV infection [30]. Other 
conditions and symptoms commonly seen in 
individuals with PHI /AHI are listed in Table 1 
alongside the study references. 
 
3.1.2.2 Sexually transmitted infections (STIs) 
and Blood Born viruses (BBVs) 
 
STIs and BBVs most commonly reported either 
prior to or at HIV diagnosis were; Hepatitis C (9 
studies), Hepatitis B (8 studies), syphilis (7 
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studies), condyloma acuminata (3 studies), 
gonorrhoea (3 studies), chlamydia (3 studies) 
and cytomegalovirus (2 studies). In studies 
reporting specific STIs, those with the highest 
prevalence in HIV positive individuals were 
syphilis, gonorrhoea and chlamydia. In     
addition, 14 studies reported STIs being 
associated with HIV infection, but did not report 
specific STIs. 
 
Syphilis was a common STI found in individuals 
with HIV infection, present in 38% of HIV infected 
patients in Tokyo [31], 11% of MSM living with 
HIV [32] and 11% of individuals newly diagnosed 
with HIV in an Italian cohort study [33].  
Gonorrhoea was also a common STI found in 
27% of those newly diagnosed with HIV from a 
London HIV clinic [34] and 67 cases of 
gonorrhoea were reported prior to diagnosis in 
1735 (3.8%) HIV infected individuals [33]. In a 
case control study of general practice databases 
in Amsterdam, gonorrhoea and syphilis were 
strongly associated with HIV infection OR 15.9, 
95% CI 2.0 to infinity and OR 39.3 95% CI 5.7 to 
1703.9 respectively [35]. Hepatitis B (HBV) and 
hepatitis C (HCV) were common BBVs 
diagnosed in individuals with HIV infection, 
among patients in Tokyo 18.9% had HBV [31], 
and in a primary care setting in Toronto among 
MSM 49.4% and 10.4% had HBV and HCV 
infection respectively [32]. Scognamiglio et al. 
found that there were 210 cases of viral hepatitis 
infections prior to diagnosis in 1735 (12%) 
individuals newly diagnosed with HIV infection. In 
a case control study identifying ICs for HIV 
infection diagnosed within hospital settings, 
strong associations were seen for hepatitis A 
(aOR 41.6 95% CI 11.7-148), non-A viral 
hepatitis (aOR 23.6, 95% CI 16.5-33.7), STIs and 
viral hepatitis (aOR 12.3 95% CI 9.60 -15.7) and 
syphilis (aOR 94.7, 95% CI 20.9-429) [36]. 
 
A nationwide population-based cohort study 
encompassing all Danish residents aged 20-60 
years during a 19-year study period estimated 
the five-year risk of an HIV diagnosis (FYRHD) 
after a first-time diagnosis of 147 pre-specified 
potential indicator diseases [37]. The study 
showed that a number of diseases were 
identified with a FYRHD >0.1% including 
infectious diseases such as syphilis and        
hepatitis which were associated with particularly 
high FYRHD. Other STIs and BBVs commonly 
seen in individuals with HIV infection are           
shown in Table 1 alongside the study   
references. 
 
3.1.2.3 Conditions associated with immuno-
suppression and cancer 
 
The most commonly reported conditions 
associated with immunosuppression and cancers 
in individuals with HIV infection were; pneumonia 
(24 studies), oral/oesophageal candidiasis (14 
studies), Kaposi sarcoma (8 studies), cervical 
dysplasia and cervical cancer (7 studies), 
lymphoma and Non-Hodgkins Lymphoma (NHL) 
(4 studies) and wasting syndrome (3 studies). 
 
Pneumonia was a common condition associated 
with immunosuppression found in HIV infected 
individuals. Bacterial pneumonia was reported in 
4% of HIV infected patients in a retrospective 
case note review in primary and secondary care 
settings [38] and in 8% of patients in a service 
evaluation of four general practices in London 
[39]. In a UK case control study of patients in 
general practices that used data from the health 
improvement network (THIN) database bacterial 
pneumonia and oral candidiasis were most 
strongly associated with HIV infection (OR 47.7, 
95% CI 5.6 to 404.2 and OR 29.4 95% CI 6.9 to 
125.5, respectively) [40]. The percentage 
prevalence of pneumocystis jiroveci pneumonia 
(PJP) in HIV infected individuals across primary, 
secondary and tertiary care settings ranged from 
9 to 29% (Fig. 1) with the highest prevalence in 
secondary care settings estimated from two 
separate studies of newly HIV infected 
individuals from retrospective reviews of patient 
medical records [20,41].  
 
Kaposi sarcoma (Fig. 2) was a common cancer 
associated with immunosuppression seen among 
HIV positive patients in primary care [39], 
secondary care [31,42,43], secondary and 
tertiary setting [44,45] and across all 3 settings 
[46]. 
 
Oral /oesophageal candidiasis and wasting 
syndrome were also frequently reported 
conditions seen either prior to or after an HIV 
positive diagnosis. A large retrospective study of 
newly infected adults in Sweden found candida 
oesophagitis and wasting syndrome to be the 
most common AIDS defining conditions [17]. In 
HIV infected late presenters (presenting with 
AIDS defining illness and/or CD4 counts of <350 
cells/µl) in Germany, 51% reported symptoms of 
candida oesophagitis and 40% with wasting 
syndrome [20]. Oral candidiasis was reported as 
a common condition in 4 studies [35,39,47,48] 
and oesophageal candidiasis in 5 studies [31,47, 
49-51].   
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Table 1. Studies showing the most commonly reported HIV indicator conditions (HIV ICs) found in HIV positive individuals and IC(s) associated with HIV infection alongside the 
corresponding study references 
 
HIV Indicator Conditions (ICs) and signs and symptoms Individual prevalence (%) & 
prevalence ranges (%) of IC(s) in 
HIV+ individualsᶧ across 
different studies 
Studies showing most common HIV IC(s) found in HIV+ individuals & IC(s) associated with HIV 
infection 
IC(s) presenting in individuals with general HIV 
infection 
IC(s) presenting in individuals with PHI or AHI 
Symptoms seen in Primary HIV infection (PHI)    
Acute Retroviral syndrome/acute HIV infection (AHI) 1 to 28% Liggett et al 2016, Sacks et al 2017  
Primary HIV Infection (PHI) 4.4 to 4.5% Dorward et al 2012, Brannstrom et al 2016   
Mononucleosis- like illness 1.7% Joore et al 2015, Menacho et al 2013*, Rayment et al 
2012*, Sullivan et al 2013*, Wellesley et al 2015*, 
Wohlgemut et al 2012*, Ellis et al 2012, Lexton & 
Cunningham 2017* 
 
Fever and Pyrexia of unknown origin  
2 to 8% (general HIV infection) 
53 to 90% (PHI /AHI) 
Champenois et al 2013, Chin et al 2013, Klein et al 
2003, Joore et al 2015, Horino et al 2016, Cropp et al 
2015, Damery et al 2013, Dorward et al 2012, 
Wohlgemut et al 2012 
Braun et al 2015, Hecht et al 2002*, Hoenigl et al 
2016, Richey & Halperin 2013, Sudarshi et al 2008 
Lymphadenopathy  
2 to 7 % (general HIV infection) 
7 to 75% (PHI/ AHI) 
Brawley et al 2013, Champenois et al 2013, Chin et al 
2013, Ellis et al 2012, Horino et al 2016, Joore et al 
2015, Klein et al 2003, Liggett et al 2016*, Rivero 
Marcotegui et al 2014, Rayment et al 2012*, Dorward 
et al 2012, Wellesley et al 2015*, Wohlgemut et al 
2012* 
Braun et al 2015, Sudarshi et al 2008, Richey & 
Halperin 2013, Wood et al 2014* 
Night sweats 2.6% (general HIV infection) 
55% (PHI/AHI) 
Klein et al 2003, Liggett et al 2016* Hoenigl et al 2016 
Opportunistic diseases 23%  Braun et al 2015 
Gastrointestinal symptoms (nausea, vomiting, diarrhoea) 14- 68%  Braun et al 2015, Hoenigl et al 2016, Sudarshi et al 
2008, Richey & Halperin 2013, Wood et al 2014* 
Neurological symptoms 12%  Braun et al 2015 
Skin soft tissue symptoms 9%  Braun et al 2015 
Respiratory symptoms 6%  Braun et al 2015 
Urogenital symptoms 3%  Braun et al 2015 
Fatigue 26 to 90%  Hoenigl et al 2016, Richey & Halperin 2013  
Elevated liver enzymes 61%  Braun et al 2015 
Pharyngitis
abc
, Flu like symptoms,
 d
 Sore throat
d
, Cough
a
 15 to 70% 
 
 Braun et al 2015
a
, Hoenigl et al 2016
b
, Richey & 
Halperin 2013
c
, Sudarshi et al 2008
d
 
Oral ulcers 12 to 20%  Braun et al 2015, Richey & Halperin 2013  
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HIV Indicator Conditions (ICs) and signs and symptoms Individual prevalence (%) & 
prevalence ranges (%) of IC(s) in 
HIV+ individualsᶧ across 
different studies 
Studies showing most common HIV IC(s) found in HIV+ individuals & IC(s) associated with HIV 
infection 
IC(s) presenting in individuals with general HIV 
infection 
IC(s) presenting in individuals with PHI or AHI 
Weight loss 22 -76%  Braun et al 2015, Hoenigl et al 2016, Richey & 
Halperin 2013, Wood et al 2014* 
Respiratory    
Respiratory tract infections 10.6 to 12% Chin et al 2013, Jenkins et al 2006, Sogaard et al 
2012* 
 
Recurrent bacterial infections 1 to 9% Champenois et al 2013, Chin et al 2013  
Pulmonary diseases Not reported Omland et al 2016*  
Tuberculosis /Pulmonary tuberculosis 0.6 to 5.5% Horino et al 2016, Ramasami et al 2012, Rivero 
Marcotegui et al 2014, Scognamiglio et al 2013, 
Valentini et al 2015, Wohlgemut et al 2012*, Raben et 
al 2015*, Liggett et al 2016* 
 
Endocarditis Not reported Sogaard et al 2012*, Omland et al 2016*  
Neurology    
CNS toxoplasmosis 0.2 to 8% Chin et al 2013, Mugavero et al 2007, Horino et al 
2016, Wohlgemut et al 2012*, Tominski et al 2016, 
Valentini et al 2015 
 
CNS infection Not reported Sogaard et al 2012*  
Cryptococcal meningitis 0.4 to 4.4% Chin et al 2013, Horino et al 2016, Mugavero et al 
2007, 
 
HIV related encephalopathy 0.7% Horino et al 2016, Lexton & Cunningham 2017*  
Progressive multifocal leukoencephalopathy 0.2 to 1% Horino et al 2016, Mugavero et al 2007  
Peripheral neuropathy 3.9% Joore et al 2015, Wohlgemut et al 2012*  
Facial nerve disorder & Neuropathy Not reported Omland et al 2012*  
Dementia 0.9% Dorward et al 2012  
Headache Not reported (general HIV 
infection) 
11 to 70% (PHI/AHI) 
Liggett et al 2016* Braun et al 2015, Sudarshi et al 2008, Hoenigl et al 
2016, Richey & Halperin 2013 
Skin    
Herpes zoster/ Varicella zoster 1.3 to 9% Agusti et al 2016*, Brannstrom et al 2016*, Damery et 
al 2013*, Horino et al 2016, Jenkins et al 2006, Joore 
et al 2015, Klein et al 2003, Rivero Marcotegui et al 
2014, Menacho et al 2013*, Read et al 2011*, Sogaard 
et al 2012*, Sullivan et al 2013*, Tominski et al 2016, 
Wellesley et al 2015*, Wohlgemut et al 2012*, Omland 
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HIV Indicator Conditions (ICs) and signs and symptoms Individual prevalence (%) & 
prevalence ranges (%) of IC(s) in 
HIV+ individualsᶧ across 
different studies 
Studies showing most common HIV IC(s) found in HIV+ individuals & IC(s) associated with HIV 
infection 
IC(s) presenting in individuals with general HIV 
infection 
IC(s) presenting in individuals with PHI or AHI 
et al 2016*, Champenois et al 2013 
Herpes simplex 0.7% Horino et al 2016, Omland et al 2016*, Liggett et al 
2016* 
 
Seborrhoeic dermatitis/ severe seborrhoeic dermatitis and 
Seborrhoeic exanthema 
1 to 4.2% Brannstrom et al 2016, Klein et al 2003, Rivero 
Marcotegui et al 2014, Scognamiglio et al 2013, 
Sullivan et al 2013*, Wellesley et al 2015*, Wohlgemut 
et al 2012*, Dorwood et al 2012, Ellis et al 2012, Gullon 
et al 2016*, Menacho et al 2013*, Joore et al 2015 
 
Soft tissue infections/skin infections 8.6% Jenkins et al 2006, Sogaard et al 2012*  
Psoriasis or severe psoriasis 1% Dorward et al 2012*, Wohlgemut et al 2012*, Joore et 
al 2015 
 
Skin lesions 4.6% Horino et al 2016  
Rash 9 to 80%  Braun et al 2015, Sudarshi et al 2008, Hoenigl et al 
2016, Hecht et al 2002*, Richey & Halperin 2013  
Molluscum contagiosum 0.4% Horino et al 2016, Read et al 2011*  
Erythema multiforme 0.2% Horino et al 2016  
Scabies 0.2% Horino et al 2016  
Dermatological infections 4.9% Jenkins et al 2006   
Blood    
Haematological disorders 1.5% Rivero Marcotegui et al 2014, Sogaard et al 2012*  
Leukocytopenia 2.9 to 24% Rayment et al 2012*, Joore et al 2015, Tominski et al 
2016 
 
Leukopenia 40%  Richey & Halperin 2013 
Blood Dyscrasia 4 to 21.5% Brannstrom et al 2016*, Brawley et al 2013, Ellis et al 
2012, Walker et al 2015*, Whittle et al 2013, Wellesley 
et al 2015*, Dorwood et al 2012 
 
Thrombocytopenia 0.9 to 22% Cropp et al 2015, Horino et al 2016, Rayment et al 
2012*, Sogaard et al 2012*, Tominski et al 2016, 
Wohlgemut et al 2012*, Omland et al 2016* 
Braun et al 2015 
Hypergammaglobulinemia 1.5% Horino et al 2016   
Leukopenia/Thrombopenia Not reported Menacho et al 2013*, Sullivan et al 2013*  
Lymphopenia/Neutropenia Not reported Read et al 2011*, Wohlgemut et al 2012*  
Co- infection with other BBVs 1.4% Cropp et al 2015  
Gastroenterology    
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HIV Indicator Conditions (ICs) and signs and symptoms Individual prevalence (%) & 
prevalence ranges (%) of IC(s) in 
HIV+ individualsᶧ across 
different studies 
Studies showing most common HIV IC(s) found in HIV+ individuals & IC(s) associated with HIV 
infection 
IC(s) presenting in individuals with general HIV 
infection 
IC(s) presenting in individuals with PHI or AHI 
Gastrointestinal diseases Not reported Omland et al 2016*  
Candida infection Not reported Sogaard et al 2012*  
Herpetic esophagitis 0.6% Rivero Marcotegui et al 2014  
Oral hairy leucoplakia 0.9% Wohlgemut et al 2012*, Dorward et al 2012  
Oral infection  2.6% Klein et al 2003  
Weight loss 1.3 to 8.8% Brawley et al 2013, Damery et al 2013*, Brannstrom et 
al 2016, Ellis et al 2012, Joore et al 2015, Liggett et al 
2016*, Walker et al 2015*, Wellesley et al 2015*, 
Champenois et al 2013, Dorward et al 2012, Klein et al 
2003, Rivero Marcotegui et al 2014, Tominski et al 
2016, Wohlgemut et al 2012*, 
 
Diarrhoea & chronic diarrhoea 1 to 9% Brawley et al 2013, Ellis et al 2012, Gullon et al 2016*, 
Rivero Marcotegui et al 2014, Wellesley et al 2015*, 
Wohlgemut et al 2012*, Champenois et al 2013, 
Damery et al 2013*, Liggett et al 2016*, Walker et al 
2015*, Joore et al 2015 
 
Cryptosporidiosis 0.2 to 1% Horino et al 2016, Mugavero et al 2007   
Sexually transmitted infections (STIs)     
STIs (general) 3.6 to 29% Brannstrom et al 2016, Champenois et al 2013, Ellis et 
al 2012, Gullon et al 2016*, Jenkins et al 2006, Rivero 
Marcotegui et al 2014, Sogaard et al 2012*, Wellesley 
et al 2015*, Wohlgemut et al 2012*, Arkell et al 2011*, 
Dorward et al 2012, Lexton & Cunningham 2017*, 
Joore et al 2015, Scognamiglio et al 2013 
 
Hepatitis Not reported Brannstrom et al 2016*, Omland et al 2016*  
Non-A viral hepatitis Not reported Sogaard et al 2012*, Omland et al 2016*  
Hepatitis A Not reported Sogaard et al 2012*, Omland et al 2016*  
Hepatitis B 2.2 to 7.3% Horino et al 2016, Rivero Marcotegui et al 2014, 
Rayment et al 2012*, Scognamiglio et al 2013, Sullivan 
et al 2013*, Wohlgemut et al 2012*, Raben et al 2015*, 
Joore et al 2015 
 
Hepatitis C 1.4 to 4.8% Agusti et al 2016*, Rivero Marcotegui et al 2014, 
Rayment et al 2012*, Read et al 2011*, Scognamiglio 
et al 2013, Sullivan et al 2013*, Wohlgemut et al 2012*, 
Raben et al 2015*, Sacks et al 2017  
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HIV Indicator Conditions (ICs) and signs and symptoms Individual prevalence (%) & 
prevalence ranges (%) of IC(s) in 
HIV+ individualsᶧ across 
different studies 
Studies showing most common HIV IC(s) found in HIV+ individuals & IC(s) associated with HIV 
infection 
IC(s) presenting in individuals with general HIV 
infection 
IC(s) presenting in individuals with PHI or AHI 
Syphilis 4.4 to 13% Agusti et al 2016*, Horino et al 2016, Joore et al 2015, 
Scognamiglio et al 2013, Sogaard et al 2012*, Omland 
et al 2016*, Sacks et al 2017  
 
Chlamydia 10.8 to 14.9% Joore et al 2015, Lexton & Cunningham 2017*, Sacks 
et al 2017 
 
Cytomegalovirus infection 0.9 to 2% Horino et al 2016, Mocroft et al 2013  
Amebic disease 2.1% Horino et al 2016  
Condyloma acuminata 2.1 to 3.9% Horino et al 2016, Joore et al 2015, Omland et al 2016*  
Gonorrhoea 3.9 to 26.6% Joore et al 2015, Scognamiglio et al 2013, Sacks et al 
2017  
 
Human papilloma virus related disease Not reported Read et al 2011*  
Genital warts 4.9% Scognamiglio et al 2013  
Genital ulcers 3%  Braun et al 2015, Wood et al 2014* 
Genital herpes 1 to 1.9% Joore et al 2015, Scognamiglio et al 2013  
Infectious vaginitis 0.1% Scognamiglio et al 2013  
GYN/STD/GU complaints 14% Liggett et al 2016  
Nonspecific symptoms    
Fatigue 2.4% Brannstrom et al 2016, Liggett et al 2016*  
Sore throat Not reported Liggett et al 2016*  
Arthropathy Not reported Liggett et al 2016*  
Myalgia 18 to 70%  Hoenigl et al 2016, Braun et al 2015, Richey & 
Halperin 2013  
Arthralgia 12 to 70%  Braun et al 2015, Sudarshi et al 2008, Hoenigl et al 
2016, Richey & Halperin 2013 
Chills Not reported Liggett et al 2016*  
Anorexia Not reported Liggett et al 2016*  
Conjunctivitis Not reported Liggett et al 2016*  
Nausea Not reported Liggett et al 2016*  
Near syncope Not reported Liggett et al 2016*  
Kidney    
HIV associated nephropathy 2.2% Ramasami et al 2012  
Conditions associated with immunosuppression & 
Cancers 
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HIV Indicator Conditions (ICs) and signs and symptoms Individual prevalence (%) & 
prevalence ranges (%) of IC(s) in 
HIV+ individualsᶧ across 
different studies 
Studies showing most common HIV IC(s) found in HIV+ individuals & IC(s) associated with HIV 
infection 
IC(s) presenting in individuals with general HIV 
infection 
IC(s) presenting in individuals with PHI or AHI 
Bacterial pneumonia 0.7 to 16.9% Brawley et al 2013, Cropp et al 2015, Damery et al 
2013*, Dorward et al 2012, Valentini et al 2015, Whittle 
et al 2013, Wellesley et al 2015*, Wohlgemut et al 
2012*, Arkell et al 2011*, Liggett et al 2016* 
 
Pneumococcal pneumonia Not reported Omland et al 2016*  
Pneumonia & recurrent pneumonia 3.4 to 8% Joore et al 2015, Klein et al 2003, Rayment et al 2012*, 
Read et al 2011*, Brannstrom et al 2016* 
 
Pneumocystis jiroveci pneumonia 9 to 29% Chin et al 2013, Horino et al 2016, Mocroft et al 2013, 
Mugavero et al 2007, Ramasami et al 2012, Valentini 
et al 2015, Walker et al 2015, Dorward et al 2012*, 
Liggett et al 2016*, Tominski et al 2016, Brannstrom et 
al 2016*, Wohlgemut et al 2012*, Lexton & 
Cunningham 2017* 
 
Oral /oesophageal candidiasis/ Candida oesophagitis 0.6 to 44% Liggett et al 2016*, Tominski et al 2016, Raben et al 
2015*, Brannstrom et al 2016, Valentini et al 2015 
Damery et al 2013*, Dorward et al 2012, Horino et al 
2016, Rivero Marcotegui et al 2014, Wellesley et al 
2015*, Wohlgemut et al 2012*, Mocroft et al 2013, Chin 
et al 2013, Joore et al 2015 
 
Wasting syndrome/ AIDS wasting syndrome 3.4 to 39.6% Brannstrom et al 2016, Tominski et al 2016, Liggett et 
al 2016* 
 
Cytomegalovirus esophagitis Not reported Liggett et al 2016*  
Ocular toxoplasmosis Not reported Liggett et al 2016*  
Toxoplasmosis of the hand  Not reported Liggett et al 2016*  
Mycobacterium avium complex 1% Chin et al 2013  
Cytomegalovirus (CMV) infection 0.9 to 13.9% Horino et al 2016, Mocroft et al 2013  
CMV retinitis Not reported Liggett et al 2016*, Wohlgemut et al 2012*  
Progressive multifocal leukoencephalopathy 0.2 to 1% Horino et al 2016, Mugavero et al 2007  
Cancers    
Lymphoma & Non-Hodgkin’s Lymphoma 0.8 to 1.8% Horino et al 2016, Mugavero et al 2007, Sullivan et al 
2013*, Raben et al 2015* 
 
Cervical dysplasia, Cervical intra-epithelial neoplasia stage III, 
Cervical carcinoma in situ/ Cervical cancer 
0.6 to 1.5% Brannstrom et al 2016*, Sullivan et al 2013*, Tominski 
et al 2016, Lexton & Cunningham 2017*, Rivero 
Marcotegui et al 2014, Raben et al 2015*, Joore et al 
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HIV Indicator Conditions (ICs) and signs and symptoms Individual prevalence (%) & 
prevalence ranges (%) of IC(s) in 
HIV+ individualsᶧ across 
different studies 
Studies showing most common HIV IC(s) found in HIV+ individuals & IC(s) associated with HIV 
infection 
IC(s) presenting in individuals with general HIV 
infection 
IC(s) presenting in individuals with PHI or AHI 
2015 
Anal cancer Not reported Brannstrom et al 2016*, Sullivan et al 2013*  
Kaposi sarcoma 0.9 to 3.3% Liggett et al 2016*, Dorward et al 2012, Wohlgemut et 
al 2012*, Lexton & Cunningham 2017* 
Dorward et al 2012*, Horino et al 2016, Mugavero et al 
2007, Ramasami et al 2012 
 
ᶧ IC(s) identified in individuals before or after receiving a HIV positive diagnosis and includes studies carried out across different healthcare settings (e,g primary, secondary and tertiary care settings) 
* % prevalence of IC(s) not included in prevalence range figures in Table 1 as data either not reported or available from the study, or the IC(s) were reported as number of episodes/ number of consultations related to the IC(s) itself 
or frequency of IC(s) only reported as odds ratios and confidence intervals. PHI: Primary HIV Infection, AHI: Acute HIV Infection 
 
 
 
Fig. 1. Prevalence of pneumocystis jiroveci pneumonia (PJP) in HIV + individuals across different healthcare settings 
1⁰ care: primary care setting, 2⁰ care: secondary care setting, 3⁰ care: tertiary care setting 
0
5
10
15
20
25
30
35
1⁰ care 
(Chin 2013)
2⁰ care 
(Horino 
2016)
2⁰ care 
(Walker 
2015)
2⁰ care 
(Tominski 
2016)
2⁰ care 
(Mugavero 
2007)
3⁰ care 
(Mocroft 
2013)
1⁰,2⁰ & 3⁰ 
care 
(Ramasami 
2012)
P
re
va
le
n
ce
 o
f 
P
JP
 (
%
)
Setting & Study Reference 
 
 
 
 
Davies et al.; ISRR, 6(2): 1-27, 2017; Article no.ISRR.36373 
 
 
 
13 
 
 
 
Fig. 2. Prevalence of Kaposi sarcoma in HIV+ individuals across different healthcare settings 
1⁰ care: primary care setting, 2⁰ care: secondary care setting, 3⁰ care: tertiary care setting 
 
3.1.2.4 Other common conditions & symptoms 
 
Other conditions and symptoms commonly 
reported were blood dyscrasias with prevalence 
in HIV infected individuals of 5% in primary care 
[39], 4% in primary and secondary care [38] and 
6.4% in tertiary care [52]. Specifically, 
thrombocytopenia was a common blood disorder 
reported in HIV infected individuals across all 
settings [20,31,36,44,53,54]. The prevalence of 
seborrhoeic dermatitis in HIV infected individuals 
ranged from 1% to 2.7% in primary care [35,39], 
4.2% in secondary care [47] and 2.1% [33] and 
2.6% [48] in tertiary care (Fig. 3). Herpes zoster 
was also commonly reported in HIV positive 
patients, with a prevalence of 6.9% in a primary 
care study [35], 1.3% [31] ,9% [20] and 5.5% [47] 
in secondary care settings and 4.6% in a tertiary 
care setting [48] (Fig. 4).  
 
Tuberculosis or pulmonary tuberculosis were 
observed in 5 studies investigating HIV ICs in 
HIV positive patients, with prevalence ranging 
from 0.6% to 5.5% across different healthcare 
settings (Fig. 5). Weight loss and diarrhoea were 
also very common symptoms and reported in 
many studies investigating HIV ICs in HIV 
positive patients prior to or after diagnosis. The
 
 
 
Fig. 3. Prevalence of seborrheic dermatitis in HIV+ individuals across different healthcare 
settings 
1⁰ care: primary care setting, 2⁰ care: secondary care setting, 3⁰ care: tertiary care setting 
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prevalence of weight loss ranged from 1.3 to 
8.8% (not including individuals with PHI/AHI) 
(Fig. 6) with the highest prevalence observed in a 
case control study in Amsterdam from a general 
practice database showing a strong association 
with HIV infection (OR 39, 95% CI 2.0 to infinity) 
[35]. In addition, the THIN study showed a strong 
association between weight loss and HIV-
infection (OR 13.4, 95% CI 5.0 to 36) [40].  
 
Prevalence of diarrhoea in HIV infected 
individuals ranged from 1% to 9% (Fig. 7) with 
the highest prevalence observed in tertiary care 
settings of newly diagnosed HIV patients, from 
retrospective audits of HIV centres in the UK [52] 
and from a French national agency for research 
on AIDS and viral hepatitis cohort (ANRS) [14]. 
 
The nationwide population study of Danish 
residents estimating FYRHD after a first-time 
diagnosis of 147 HIV ICs [37] found that 
endocarditis, several pulmonary vascular 
diseases and haematological diseases 
(particularly in males) (e.g thrombocytopenia) 
were also associated with an FYRHD >0.1%. 
Gastrointestinal disease in older males, and
 
 
 
Fig. 4. Prevalence of herpes zoster in HIV+ individuals across different healthcare settings 
1⁰ care: primary care setting, 2⁰ care: secondary care setting, 3⁰ care: tertiary care setting 
 
 
 
Fig. 5. Prevalence of Tuberculosis in HIV+ individuals across different healthcare settings 
1⁰ care: primary care setting, 2⁰ care: secondary care setting, 3⁰ care: tertiary care setting 
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facial nerve disorder and neuropathy in males 
were associated with an FYRHD >0.1%. 
 
3.2 Interventions Using HIV ICs to Guide 
HIV Testing and Case Finding 
 
3.2.1 Characteristics of the studies 
 
We found 12 intervention studies that had used 
HIV ICs as markers or flags either in isolation or 
alongside other risk factors to guide HIV testing 
and case finding (Table 2). Studies are 
presented in reverse chronological order with the 
most recent study at the top of the table. The 
table shows for each study: reference and 
location, study design, intervention & 
comparison, target population, number or 
percentage with ICs, HIV test rate, number/rate 
of HIV positive diagnoses and a description of 
the main study objectives and outcomes.  
 
Articles describing studies included ten peer 
reviewed papers and two abstracts from BHIVA 
conference proceedings (n=2). Locations of 
included studies were as follows; within Europe 
including the UK (n=2), Spain (n=3), Belgium
 
 
 
Fig. 6. Prevalence of weight loss in HIV+ individuals across different healthcare settings 
1⁰ care: primary care setting, 2⁰ care: secondary care setting, 3⁰ care: tertiary care setting 
 
 
 
Fig. 7. Prevalence of diarrhoea in HIV+ individuals across different healthcare settings 
1⁰ care: primary care setting, 2⁰ care: secondary care setting, 3⁰ care: tertiary care setting 
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(n=1), and the USA (n=6), which included 
Colorado (n=1), Connecticut (n=1), Chicago 
(n=1), Washington state (n=1), and multiple cities 
across USA (n=2). The types of interventions 
included: electronic clinical decision support 
system & clinical reminders (n=4), risk prediction 
tools (n=3), training sessions on ICs and 
participation in the HIDES study (n=1), education 
sessions alongside case note prompts of patients 
with ICs (n=1), rapid HIV testing based on 
presence of an IC (n=2) and HIV risk exposure 
and IC questionnaire to support targeted 
screening (n=1). These studies took place in the 
following settings, primary care (n=3), secondary 
care (n=2), primary care centres and emergency 
department (n=1), primary and secondary care 
settings (n=1), STD clinics (n=2), Veterans affairs 
healthcare system (n=2), high risk participants 
from the HIV Network for prevention Trials 
(HIVNET) Vaccine Preparedness study (n=1). 
 
3.2.2 Effectiveness of Interventions using HIV 
ICs to guide HIV testing  
 
The majority of studies showed that interventions 
using HIV ICs to guide testing were successful in 
increasing testing rates and the number of HIV 
positives identified (Table 2). Federman et al. 
assessed the effectiveness of an electronic 
clinical reminder added to the medical records 
within the Veteran’s affairs (VA) healthcare 
system in the USA [55]. The reminder was based 
on risk factors for HIV (high risk sexual 
behaviour, alcohol or substance use disorders) 
as well as hepatitis and other sexually 
transmitted diseases (STDs). Testing based on 
the use of the reminder led to the diagnosis of 
HIV in 24 patients over a 19-month period and 
testing increased by 369%. Another study based 
in the USA by Schrantz et al (2011), developed a 
web based patient tracking software to flag 
selected patients for testing. Selection criteria 
included presenting with STIs, pregnancy, 
symptoms of an HIV IC, bacterial pneumonia (in 
<65-year olds), people who inject drugs (PWID) 
and MSM. The study showed a strong 
association between the use of the system and a 
262% increase in testing frequency (from 29.6 to 
80.5 tests per month) [56]. 
 
An intervention developed by Goetz et al (2008) 
using a clinical reminder triggered by prior 
evidence of hepatitis B or C, STDs (gonorrhoea, 
chlamydia, syphilis or genital herpes) with other 
behavioural risk factors (e.g drug use) showed 
that the use of clinical reminders increased the 
frequency of testing and the number of new 
diagnoses made. They tested the intervention in 
five veterans’ healthcare administration facilities 
(2 intervention, 3 controls). At the two 
intervention sites testing increased from 4.8% to 
10.8% and 5.5% to 12.8% with new HIV 
diagnoses doubling from 15 to 30 among at-risk 
individuals comparing the years pre-and post-
intervention [57]. A later evaluation study found 
that the impact on HIV testing rates was fully 
sustainable and that providers became more 
proficient at offering and discussing HIV tests 
[58]. 
 
Branch et al., carried out a study to assess the 
feasibility and acceptability of an electronic 
clinical decision support system prompting HIV 
testing for use in hospital and general practice. 
An algorithm was devised so that when certain 
tests were selected (e.g hepatitis serology) a 
screen prompt would suggest also offering an 
HIV test. Evaluation interviews with the doctors 
and nurses conducted after a 3-month trial period 
found that the prompt was generally acceptable 
and was considered useful and educational. 
Nurses reported that they were less comfortable 
responding to the prompt in situations where they 
thought testing was not justified. However, only 
between 1% and 2% of all prompts were 
accepted by the HCP. No positive HIV tests 
resulted from the prompts, but the number of 
tests ordered increased by 6% in the primary 
care setting compared to the previous 9 months 
before the trial (p=0.165). This study is currently 
being developed further to refine the application 
to provide more accurate risk stratification [59].  
 
Cayuelas-Redondo et al. undertook an 
intervention to raise awareness of IC guided HIV 
testing that consisted of training sessions and 
participation in the HIDES study in 3 primary care 
centres (PCCs). They analysed whether the 
intervention in this multicentre retrospective 
study influenced the proportion of HIV serology 
requested. The number of HIV tests in patients 
with an IC was 3.9% pre-intervention in 2008 and 
increased to 11.8% post-intervention in 2012 (P< 
.0001). The HIV infection rate was 2.2% (95% CI 
:0.4-7.3) (n=2). Although the requests for HIV 
tests tripled in number there were a further 88% 
of cases where a test should have been offered, 
and a further 25 new cases would have been 
diagnosed between 2008 and 2012 if a test had 
been offered to all patients with an IC [60]. 
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Table 2. Interventions using HIV clinical indicators to increase HIV testing and increase case-finding (n=12) 
 
Reference & Study 
location 
Study Type 
and 
Intervention 
Intervention 
/Comparison 
Population targeted 
 
No. or % with ICs,  
No. or % HIV+,  
HIV test rate 
Main objective and outcome of study 
Branch et al 2016 [59], 
UK (BHIVA abstract) 
(recently published 
paper: Chadwick et al 
2017[85] 
Feasibility 
study  
Electronic clinical 
decision support 
system (CDSS) 
Patients from 2 clinical 
settings (Chelsea & 
Westminster (C & W) 
Hospital & Teeside 
primary care 
 
No HIV+ tests resulted from 
prompted requests, No. of tests 
ordered were 6% higher in the 
trial period in Teeside 
compared to the previous 9 
months 
Objective: to assess the feasibility of a prototype CDSS application 
prompting HIV testing based on Drs/Nurses selecting certain tests 
(e.g. when hepatitis serology selected). Outcome: The system was 
found to be both useable and acceptable to hospital doctors, GPs 
and nurses with little evidence of prompt/alert fatigue. In general 
practices, around 1 in 10 prompts were accepted and there was a 
6% increase in testing rates over the 3-month study period 
(P=0.169). Further development to include additional clinical data 
and refining application to provide more accurate risk stratification 
Elias et al 2016 [63], 
Madrid, Spain 
Prospective, 
one arm, open 
label study 
HIV risk exposure and 
IC (HIV RE&IC) 
Questionnaire to 
support targeted HIV 
screening 
Patients attending 
emergency room or PCC 
Confirmed hidden HIV infection 
was detected in 4.1%, while 
HIV RE&IC was positive in 
51.2%. 5329 valid paired HIV 
RE&IC Questionnaires and 
rapid HIV tests were 
performed. 3694 (69.3%) in the 
PCC 
Objective: a feasibility study using an HIV risk exposure and 
indicator condition (HIV RE&IC) questionnaire to support targeted 
HIV screening. All enrolled patients filled out a questionnaire and 
were HIV tested. Outcome: The HIV RE&IC questionnaire 
sensitivity was 100% to predict HIV infection, with a 100% negative 
predictive value. When considered separately RE or IC items 
sensitivity decreases to 86.4% or 91% & NPP to 99.9% for both of 
them. Questionnaire accurately discriminated all non-HIV infected 
people without missing any HIV diagnoses 
Cayuelas-Redondo et al 
2015 [60], Spain 
Multicentre 
retrospective 
review 
Retrospective review 
was conducted 
comparing the baseline 
(3 primary care centres 
(PCC) in 2008) and a 
post-collaboration 
period (3 PCC in 2012). 
The collaboration 
consisted of training 
sessions and 
participation in the 
HIDES study 
3 PCC in Spain involved 
in collaboration to raise 
awareness of early 
detection of HIV (HIDES 
study) 
1219 ICs were included (558 in 
2008 and 661 in 2012) In 2008: 
No. of HIV tests in patients with 
an IC was 3.9% and rose to 
11.8% in 2012 (P< .0001). HIV 
infection rate was 2.2%. 
Estimated that 25 new cases 
(12 in 2008 and 13 in 2012) 
would have been diagnosed if 
test had been performed on all 
patients with ICs. 
Objective: to analyse whether a collaboration to raise awareness of 
the importance of early detection of HIV in 3 primary care centres 
influenced the proportion of HIV serology requested. Outcome: 
Predictors of HIV request were having an IC in 2012, a younger 
age, having a mononucleosis syndrome and not being Spanish. The 
HIV request demand tripled after the collaboration with primary care 
centres, however in 88% of patients the test was not requested, 
resulting in diagnostic losses. 
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Reference & Study 
location 
Study Type 
and 
Intervention 
Intervention 
/Comparison 
Population targeted 
 
No. or % with ICs,  
No. or % HIV+,  
HIV test rate 
Main objective and outcome of study 
Dosekun et al 2013 
[61], Brighton, UK 
(BHIVA abstract) 
A two-stage 
prospective 
study  
Clinicians received an 
education programme 
about significance of 
late HIV diagnosis, 
highlighting ICs 
relevant to their field. 
Stage 1 consisted of 
pre-identification of IC 
& insertion of a prompt 
to offer HIV test. Stage 
2 relied on clinician 
identification of IC only 
(no prompt) 
Patients attending 
outpatient clinic 
(Dermatology, 
Gastroenterology, 
Haematology) at 2 
university hospitals. 
(4191 eligible patients) 
Test offer and uptake rate was 
compared with/without prompts 
and across age, gender and 
ethnic groups. 608 (14.5%) 
identified to have ICs of whom 
25 (4.1%) were HIV+. Overall 
test offer was 17.5% and was 
significantly higher during the 
prompt stage 
Objective: to assess the impact of targeted outpatient clinics 
educational programme with and without additional individual case 
note prompts for patients with ICs as a strategy to increase HIV 
testing.  Outcome: overall test offer was 17.5% and was 
significantly higher during the prompt stage (34%) vs education 
alone (3.1%) (p<0.001). Individual case note prompts significantly 
increased test offer rates 
Gennotte et al 2013 
[62], Belgium 
Multicentre 
prospective 
study 
Educational 
intervention based on 
presence of IC to 
prompt testing 
GPs and patients in area 
of Brussels 
29% had an IC, sero-
prevalence was 1.5% among 
patients with an IC. The rate of 
new diagnoses was 0.5% for 
the rapid HIV test & 0.5% for 
the standard HIV test 
Objective: to assess feasibility and acceptability of HIV screening 
through rapid tests to both GPs and patients. 10 GPs were trained 
in rapid HIV testing in area of Brussels with a substantial African 
community. One of the inclusion criteria being presence of ICs as 
defined by HIDES, to determine the number of new HIV infections 
diagnosed among tested patients. Outcome: Drs assessment: 
greater understanding of and ease in performing the testing 
procedure after 6 months of training support than after just 1 month. 
GPs felt more comfortable offering a test based on risk or the 
presence of IC and more comfortable performing the test. Both 
standard and rapid tests were well received by patients but were 
usually not offered due to time constraints  
Menacho et al 2013 
[24], Barcelona, Spain 
 
 
 
Multicentre 
prospective 
study 
Compared 
prospectively IC guided 
testing (4 preselected 
ICs) versus testing of 
those with non-ICs 
(NIC) 
Patients aged 18 to 
65yrs attending 4 PCCs 
in Barcelona, Spain 
During study period 775 
patients attended with one of 
the 4 selected ICs and 66,043 
presented with NIC. HIV 
screening was offered to 89 
patients with ICs (offer rate 
11.5%) of whom 100% 
completed testing. In the NIC 
group a test was offered to 344 
(offer rate 5.2%) of whom 97% 
completed testing. 4 HIV+ tests 
Objective: to compare prospectively IC guided testing versus 
testing of those with non-ICs using rapid finger- stick test, 4 ICs 
were selected these included: new herpes zoster infection, 
seborrheic eczema, mononucleosis syndrome or leukopenia 
/thrombocytopenia. Outcome: prevalence of HIV in IC group was 
4.7% (95% CI: 1.3-11.6%) and in NIC group was 0.3% (95% CI 
0.01-1.82 P<0.009). Although number of patients in study was 
small, IC guided HIV testing, based on 4 selected ICs, in PCCs 
seems to be a more feasible and less expensive strategy to improve 
diagnosis of HIV infection in Spain than a nontargeted HIV testing 
strategy. 
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Reference & Study 
location 
Study Type 
and 
Intervention 
Intervention 
/Comparison 
Population targeted 
 
No. or % with ICs,  
No. or % HIV+,  
HIV test rate 
Main objective and outcome of study 
in IC group and 1 HIV+ in NIC 
group 
Haukoos et al 2012 
[64], Denver, Colorado 
Analysis of 
large, 
prospectively 
collected data 
Clinical prediction tool 
to categorise patients 
into risk groups of HIV 
infection 
Patient data from a 
metropolitan STD clinic 
The derivation sample 
consisted of 92,635 patients of 
whom 504 (0.54%) were 
diagnosed HIV+. Validation 
sample consisted of 22,983 
patients of whom 168 (0.73%) 
were HIV + 
Objective: to evaluate a clinically relevant prediction tool to 
accurately categorize patients into risk groups for undiagnosed HIV 
infection: collected data on demographic characteristics, symptoms, 
history of STIs, sexual history, sexual practices, HIV testing history 
& other risk factors. Outcome: The risk scores accurately 
categorised patients into groups with increasing probabilities of 
infection 
Federman et al 
2012[55], Connecticut, 
USA 
Prospective 
study 
Electronic clinical 
reminder 
All patients enrolled in 
the VA Connecticut 
healthcare system 
Addition of a clinical reminder 
to the electronic medical record 
increased the amount of testing 
for HIV by 369%. 24 were 
diagnosed as HIV+ 
Objective: to assess effectiveness of an electronic clinical reminder 
added to medical records within the Veterans Affairs (VA) 
healthcare system (based on risk factors for HIV: Hepatitis, STDs, 
high risk sexual behaviour, alcohol or substance use disorders). 
Outcome: Testing led to the diagnosis of HIV in 24 patients over a 
19-month period and were able to increase testing by 369%. The 
reminder was highly effective in those aged 64yrs or less but less 
evidence that it was effective for increasing HIV detection in those 
aged 65 or more. 
Schrantz et al 2011 
[56], Chicago, USA 
Retrospective 
review of data 
from clinical 
and quality 
assurance 
records 
HIV testing model 
using a web based 
patient tracker software 
Patients in the 
Emergency Dept. (ED) 
103,475 patients visited the ED 
(Jan 07-Nov 08) of which 1258 
resulted in HIV testing and 54 
were positive for HIV antibody. 
Among flagged patients, 39% 
had STIs, 11% had bacterial 
pneumonia. 262% increase in 
testing frequency 
Objective: developed an Emergency Dept. HIV testing model using 
a web based patient tracking software (TRACKER) used for 
flagging selected patients for testing. Patient selection criteria 
included symptoms consistent with STIs, pregnancy, symptoms of 
bacterial pneumonia in <65yrs, IDUs and MSMs. Outcome: Strong 
association between the implementation of the system and a 262% 
increase in testing frequency (from 29.6 to 80.5 tests/month) 
Menza et al 2009 [65], 
Washington State, USA 
Data from 
medical 
records 
Prediction/risk score 
model for HIV 
Medical records data on 
MSM from an STD clinic 
Of 1903 MSM tested more than 
once for HIV, 101 acquired HIV 
over 6.7yrs of follow up. Annual 
HIV incidence was 2.57%. 
During 4 yrs. follow up in 
control arm, of 2081, 144 
acquired HIV with an incidence 
of 2.32% 
Objective: to develop a prediction model for HIV acquisition in 
MSM (collected information on demographic variables, substance 
use, STD history, sexual behaviour & sexual partners). Outcome: A 
new risk score was predictive of HIV acquisition in MSM 
Goetz et al 2008 [57], 4 
cities across USA 
Prospective 
study 
Clinical reminder 
intervention 
Persons receiving 
healthcare at 5 veteran’s 
At the 2 intervention sites 
testing increased from 4.8% to 
Objective: A multicomponent intervention (real time electronic 
clinical reminder that encourages HIV testing and feedback reports 
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Reference & Study 
location 
Study Type 
and 
Intervention 
Intervention 
/Comparison 
Population targeted 
 
No. or % with ICs,  
No. or % HIV+,  
HIV test rate 
Main objective and outcome of study 
health administration 
facilities (2 intervention, 3 
controls) between 2004 
and 2006 who were at 
risk of HIV but had not 
been previously tested 
for HIV infection 
10.8% and from 5.5% to 
12.8%. 15 new HIV diagnoses 
were made in year pre-
intervention vs 30 post 
intervention year. 
and provider activation program). Clinical reminders were triggered 
by prior evidence of Hepatitis B or C infection, illicit drug use, STD 
(gonorrhoea, chlamydia, syphilis, or genital herpes & behavioural 
risk factors). Outcome: Use of clinical reminders increased the 
frequency of testing and number of new HIV diagnoses.   
Sharghi et al 2005 [66], 
Cities across USA 
A prospective 
cohort study 
A clinical algorithm to 
predict early HIV-1 
infection. 
Study enrolled HIV-1 
negative individuals at 
risk of HIV-1 infection.  
(4652 study participants) 
86 individuals (13 women, 73 
men) seroconverted during the 
study. The overall 
seroconversion rate was 1.3 
per 100-person years 
Objective: to look at association between self-reported clinical 
factors and recent HIV-1 seroconversion. Participants had to fill out 
a questionnaire at baseline. Study developed a clinical algorithm to 
predict early HIV-1 infection. HIV-1 seroconversion diagnosed using 
ELISA and confirmed by western blotting. Outcome: Four self-
reported clinical factors were significantly associated with HIV-1 
seroconversion in multivariable analyses: recent history of 
chlamydia infection or gonorrhoea, recent fever or night sweats, 
belief of recent HIV exposure and recent illness lasting >3 days. 
Two scoring systems, based on the presence of either 4 or 11 
clinical factors were developed. Sensitivity ranged from 2.3% (with 
PPV of 12.5%) to 72.1% (with a PPV of 1%). Seroconversion rates 
were directly associated with the number of these clinical factors 
IC: indicator condition, NIC: non-indicator condition, ED: Emergency Dept, STD: sexually transmitted disease, STIs: sexually transmitted infections, PPV: Positive predictive value, NPP: Negative predictive value, MSM: Men who 
have sex with men, ELISA: Enzyme linked immunosorbent assay, VA: veteran’s affairs, CDSS: clinical decision support system, PCC: Primary care centre, HIDES: HIV indicator diseases across Europe study, CI: Confidence 
interval 
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Dosekun and colleagues assessed the impact of 
a targeted education programme for clinicians 
regarding late HIV diagnosis and awareness of 
HIV ICs with and without additional case note 
prompts for patients with ICs. They found that  
test offer was significantly higher when prompts 
were additionally used (34%) compared with 
education alone (3.1%) (p<0.001) [61]. However, 
Genotte et al (2013) also used education 
sessions to raise awareness of ICs and to 
assess whether HIV screening using rapid tests 
was feasible and acceptable (based on risk or 
presence of ICs) to a mainly African community. 
Although GPs felt more comfortable offering a 
test based on risk or presence of an IC, the study 
found that testing was usually not offered by the 
GPs due to time constraints [62].  
 
Two studies used more targeted approaches to 
HIV testing using preselected ICs [24,63]. Elias 
and colleagues developed an HIV risk exposure 
and ICs questionnaire using 14 preselected ICs 
to support targeted screening. The study found 
that the self-completed questionnaire was 
feasible and accurately discriminated all non-HIV 
infected people without missing any HIV 
diagnoses in a low prevalence area [63]. In 
primary care settings in Spain, Menacho et al. 
prospectively compared IC guided testing using 4 
preselected ICs (herpes zoster, seborrhoeic 
eczema, mononucleosis syndrome and 
leukopenia/ thrombocytopenia) with random 
testing using rapid finger stick tests. The study 
found using ICs was a feasible and less 
expensive way to improve diagnosis of HIV 
infection compared with a non-targeted approach 
[24].  
  
We also identified a number of studies that 
developed risk prediction tools to identify 
individuals at risk of HIV infection based on HIV 
ICs and other risk factors [64-66]. HIV ICs used 
for these risk predictions tools mainly 
incorporated history of fever, STIs and STDs 
(included chlamydia, gonorrhoea and syphilis). 
Other behavioural risk factors incorporated in the 
tools included sexual behaviour/practices, 
number of sexual partners, PWID and substance 
use. These prediction models were successful in 
accurately categorising patients at increasing 
probabilities of infection [64,66]  and risk scores 
were predictive of HIV acquisition in MSM [65]. 
 
4. DISCUSSION 
 
Increasing HIV testing is crucial for identifying 
individuals who remain undiagnosed and linking 
them to care and treatment with ART. This is 
important for their own health and because 
treatment with ART substantially reduces risk of 
further transmission of the virus [67]. In the USA, 
the current guidance is for routine testing among 
all adults that come into contact with the 
healthcare system [11]  but this is thought not to 
be best practice for the majority of European 
settings due to the poor cost-benefit ratio in 
certain areas where prevalence of HIV is low 
[68].  In the UK and Europe, HIV testing is 
recommended for individuals presenting with ICs 
associated with HIV infection [19,21]. The HIV in 
Europe initiative states that HIV testing of any 
person presenting with a condition associated 
with an undiagnosed HIV prevalence of >0.1% is 
cost-effective and promotes earlier diagnosis of 
HIV infection [21]. In the UK the 2008 BHIVA 
guidelines [10] were published with the aim of 
increasing HIV testing across healthcare settings 
to reduce the number of individuals with 
undiagnosed HIV infection. Routine testing in the 
UK is recommended in areas with > 2 per 1000 
population prevalence based on cost 
effectiveness studies of HIV testing in the USA 
and France [69-71]. Regardless of local 
prevalence, testing should be offered to those 
presenting with any HIV ICs and/or other risk 
factors [10]. However, studies and reviews have 
shown there is a general lack of awareness and 
knowledge of the 2008 guidelines by HCPs [72-
74]. Previous reviews and audits [75,76] show 
that adherence and application of these 
guidelines is poor, during the eight years after 
their publication, mainly due to limited test offer 
and lack of knowledge of HIV ICs by the HCP 
[75,77-79]. 
 
In this review, we have drawn together the most 
common HIV ICs and diseases that are most 
frequently seen in HIV infected individuals prior 
to or after receiving an HIV diagnosis. The most 
common ICs identified in those with PHI /AHI 
were fever/pyrexia of unknown origin [25-
27,29,30], lymphadenopathy [25-28], headache 
[25-27,29], rash  [25-27,29,30], weight loss 
[25,27-29], and gastrointestinal symptoms 
(nausea, vomiting, and diarrhoea) [25-29]. The 
strongest associations with HIV infection were 
seen for weight loss, vomiting, lymphadenopathy, 
fever and rash [28,30]. The most commonly 
reported STIs and BBVs in HIV infected 
individuals (either prior to or after diagnosis) 
were hepatitis C  [22,23,33,34,44,47,54,80,81], 
hepatitis B [22,23,31,33,35,44,47,54], syphilis 
[31,33-37,80], chlamydia [34,35,45], gonorrhoea 
[33-35], condyloma acuminate [31,35,37], 
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cytomegalovirus  [31,49] and genital herpes 
[33,35]. The strongest associations with HIV 
infection were seen for syphilis, gonorrhoea, 
hepatitis B/C and condyloma acuminata. The 
most common conditions associated with 
immunosuppression in individuals with HIV 
infection were pneumonia  [17,20,31,35,37-46, 
48-51,53,54,81-84], oral/oesophageal 
candidiasis [17,20,23,31,35,39,40,42,44,47,49-
51,83],  Kaposi sarcoma [31,39,42-46], 
lymphoma and non-Hodgkins lymphoma (NHL) 
[22,23,31,43], wasting syndrome [17, 20, 42] and 
cervical dysplasia/cervical cancer [17, 20, 22, 23, 
35,45,47]. The conditions most strongly 
associated with immunosuppression were 
pneumonia, (incl, pneumocystis jiroveci 
pneumonia and bacterial pneumonia), oral 
candidiasis/candida oesophagitis, wasting 
syndrome and cytomegalovirus.  
 
Interventions that incorporate HIV IC guided 
testing are especially warranted in areas of low 
HIV prevalence where HCPs are less familiar 
with HIV testing. Indeed, Chadwick et al. 
reported that a clinical decision support system 
(CDSS) prompt acted as a useful reminder for 
GPs to offer an HIV test in a low prevalence area 
(<0.5%) and was shown to have significant 
potential to increase HIV testing in such areas 
[85]. This review shows that HIV ICs have the 
potential to be used more effectively to guide HIV 
testing.  Evidence from numerous studies have 
shown that had testing been offered to those 
presenting with an HIV IC, a high proportion of 
individuals between 21% and 37% [17,20] would 
have received a much earlier diagnosis.  A study 
reviewing medical encounters before HIV 
diagnosis in the USA revealed that increased 
recognition of ICs for HIV testing prompted 
earlier HIV diagnosis in 22% of individuals [48]. 
Approximately 30% of newly diagnosed adults 
with HIV infection reported at least one IC before 
HIV diagnosis and that being tested for HIV 
within 6 months of being diagnosed with an IC 
reduced risk of late HIV presentation by 50% 
[33]. Results from the HIDES I and II studies 
[22,23] showed that patients with preselected 
indicator diseases had an HIV prevalence of 
>0.1%, providing firm evidence that IC guided 
testing provides a valuable opportunity to identify 
individuals with HIV infection. 
 
In the UK, the National Institute for Health Care 
Excellence (NICE) have recently produced a 
draft quality standard document [9] 
(https://www.nice.org.uk/guidance/GID-
QS10040/documents/draft-quality-standard) to 
encourage uptake of HIV testing which is due to 
be published in August 2017. It discusses 
interventions to improve the uptake of HIV testing 
among adults and young people that may have 
undiagnosed infection. This document has 
produced a list of HIV ICs which should be 
prioritised from the longer list identified by HIV in 
Europe Initiative.  One of 6 questions open to 
consultation is ‘We have identified indicator 
conditions that could be a priority for local 
measurement from the longer list of indicator 
conditions identified by HIV in Europe. Will it be 
practical to implement this?’. The list includes 
HIV ICs that service providers may wish to focus 
on as priorities, feedback from this document will 
be useful to aid any future interventions to 
improve uptake of HIV testing. Prioritising and 
focusing on HIV ICs that commonly present 
themselves could better inform testing strategies 
to identify HIV infected patients. Indeed, work is 
in progress to update guidelines for specialities 
other than HIV, such as dermatology or cancer, 
for the management of HIV ICs and AIDS 
defining conditions (ADCs), with a recent study 
showing that HIV testing was only recommended 
in 6 out of 17 guidelines for treating conditions 
that are also ADCs (35%) and 24 of 61 
guidelines for treating conditions that are also 
HIV ICs (39%) [86]. 
 
The studies on common HIV ICs and diseases 
reviewed here provide information on using them 
as important indicators of potential underlying 
HIV infection, which could be used within 
prediction tools to flag that an HIV test should be 
offered, giving a more targeted approach to 
testing. Computer prompts avoid the HCP having 
to make a personal judgment on the risk of HIV 
and provides a platform for discussing having an 
HIV test, based on a prediction model ,which 
addresses some of the barriers to testing that are 
commonly reported by HCPs [74]. Interventions 
that have used ICs as a guide to testing (as well 
as other risk factors for HIV) alongside provider 
education sessions to improve awareness of HIV 
ICs are more effective in increasing HIV testing 
rates than education alone. Education and 
training of HCPs needs to continue and should 
focus on HIV ICs most likely to be encountered in 
primary care to help reduce incidence of late 
diagnosis. Strategies or interventions that 
empower or prompt GPs to test and enhance 
awareness of the national guidelines for IC HIV 
testing may help to find those with undiagnosed 
infection and reduce late diagnosis of HIV. 
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5. LIMITATIONS 
 
This review is not a full review as it only includes 
grey literature from BHIVA conference 
proceedings (2010 to 2017) and articles included 
in the review are those that have encompassed 
the search term keywords outlined in the 
methods section (found within the article title, 
keywords or abstract). Therefore, some relevant 
articles may not be included. However, further 
articles were found by hand searching article 
reference lists. Comparing studies in this review 
should be interpreted with caution due to the 
different HIV testing guidelines, methodologies 
used to collect the data and possible differences 
in condition/disease prevalence between and 
within countries.   
 
6. CONCLUSIONS AND RECOMMENDA-
TIONS 
 
This review provides a summary of important 
information for early detection strategies so that 
HIV infected individuals can receive a timely HIV 
test. Increased awareness of HIV infection within 
the primary care setting is paramount and could 
be improved by using computer 
prompts/reminders based on common HIV ICs to 
aid the HCP in appropriate offering of an HIV 
test. More targeted testing for HIV based on 
diagnosis of an HIV IC is an important strategy 
which has been shown to be effective and could 
potentially help reduce onward transmission and 
help control the HIV epidemic. 
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